May 2020

Abstract

AACR Annual Meeting

Association of BRCA alteration type with real-world outcomes to PARP inhibitors in patients with metastatic castrate-resistant prostate cancer

Antonarakis, ES, Madison, RW, Snider, J, Snow, T, Sokol, ES, Chung, JH, McCusker, M, Singal, G, Alexander, BM, Castellanos, EH, Venstrom, JM, Schrock, AB, Ross, JS

May 2020

Abstract

ASCO Annual Meeting

Flatiron-authored

May 2020

Abstract

ASCO Annual Meeting

May 2020

Abstract

ASCO Annual Meeting

May 2020

Abstract

ASCO Annual Meeting

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

Shore, ND, Higano, CS, George, DJ, Sternberg, CN, Saad, F, Tombal, B, Miller, K, Kalinovsky, J, Jiao, X, Tangirala, K, Sartor, AO

May 2020

Manuscript

Prostate Cancer and Prostatic Diseases

Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States

George, DJ, Sartor, AO, Miller, K, Saad, F, Tombal, B, Kalinovsky, J, Jiao, X, Tangirala, K, Sternberg, CN, Higano, CS

January 2020

Manuscript

Clinical Genitourinary Cancer

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

October 2018

Abstract

ESMO Annual Congress

February 2018

Manuscript

Clinical Therapeutics

Flatiron-authored

Treatment Dynamics of Bone-Targeting Agents Among Men with Bone Metastases from Prostate Cancer in the United States

Butler A, Cetin K, Hernandez RK, Reams D, Overman R, Kim J, Hirsch B, Abernethy AP, Liede A, Brookhart A

January 2018

Manuscript

Pharmacoepidemiology & Drug Safety

Flatiron-authored

Concomitant use of emerging therapies and bone-targeting agents in prostate cancer: Observations from real-world data

Finelli, A, Hernandez, RK, Lethen, J, Wade, SW, Warner, D, Abernethy, AP, Liede, A

June 2016

Abstract

Meeting of the Canadian Urological Association

Flatiron-authored

Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer

Butler A, Ceitin K, Hernandez RK, Overman R, Kim J, Reams D, Hirsch B, Abernethy AP, Liede A, Brookhart A

June 2016

Abstract

ASCO Annual Meeting

Flatiron-authored